ArticleCancer cell international2025
Identification of SAMD9 as an adaptive response gene to environmental changes and its association with overall survival and immunotherapeutic response in glioblastoma.
Article in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundHypoxia and immune-suppressive microenvironments in glioblastoma drive transcriptional plasticity and phenotypic transition. Understanding these processes is crucial for overcoming therapy resistance and tumor relapse. This study investigates the expression pattern of sterile alpha motif domain-containing 9 (SAMD9) under these conditions, evaluates its prognostic value and spatial distribution, and explores its therapeutic implications.
methodsWe analyzed SAMD9 expression and its prognostic value across three independent IDH-wildtype glioblastoma cohorts and validated findings via immunohistochemistry in human glioma tissues. We mapped its spatial distribution using the IvyGAP database and leveraged integrated single-cell and spatial transcriptomic data to delineate local cellular interactions. Drug sensitivities were predicted using the oncoPredict package, and molecular docking was performed with Autodock for drug screening. Key findings regarding SAMD9 expression and its inducers were experimentally validated.
resultsSAMD9 was prominently expressed in an immune-suppressive subset of glioma tumor cells and was strongly associated with an interferon (IFN) signature. Elevated levels of SAMD9 correlated with reduced efficacy of anti-PD-1 treatment. Spatial mapping revealed that SAMD9 was predominantly distributed in regions of microvessel proliferation and peri-necrotic niches, where SAMD9-positive tumor cells actively interacted with vascular cells and tumor-associated macrophages (TAMs). Hypoxia and TAM co-culture significantly upregulated SAMD9, suggesting a mechanism for Bevacizumab resistance. SAMD9-high tumors exhibited TAM-dominated immune infiltration, confirmed by immune signatures profiling and histological staining. Drug prediction and molecular docking identified the multi-kinase inhibitor Dasatinib as a promising therapeutic agent for SAMD9-high IDH-wildtype glioblastoma.
conclusionsSAMD9 emerges as an adaptive response gene to environmental changes, exhibiting a significant immunomodulatory function, which highlights its promise as a therapeutic target for IDH-wildtype glioblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.